Kymera Therapeutics [KYMR] vs Corcept Therapeutics [CORT] Detailed Stock Comparison
Kymera Therapeutics
NASDAQ
Loading...
Corcept Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Kymera Therapeutics wins in 3 metrics, Corcept Therapeutics wins in 14 metrics, with 0 ties. Corcept Therapeutics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Kymera Therapeutics | Corcept Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -19.43 | 78.71 | Kymera Therapeutics |
| Price-to-Book Ratio | 4.21 | 14.60 | Kymera Therapeutics |
| Debt-to-Equity Ratio | 8.82 | 1.04 | Corcept Therapeutics |
| PEG Ratio | -0.30 | -26.76 | Corcept Therapeutics |
| EV/EBITDA | -11.67 | 87.24 | Kymera Therapeutics |
| Profit Margin (TTM) | 0.00% | 18.67% | Corcept Therapeutics |
| Operating Margin (TTM) | -736.82% | 13.72% | Corcept Therapeutics |
| EBITDA Margin (TTM) | N/A | 13.72% | N/A |
| Return on Equity | -33.26% | 21.70% | Corcept Therapeutics |
| Return on Assets (TTM) | -19.92% | 8.36% | Corcept Therapeutics |
| Free Cash Flow (TTM) | $-207.34M | $195.90M | Corcept Therapeutics |
| 1-Year Return | 27.83% | 97.78% | Corcept Therapeutics |
| Price-to-Sales Ratio (TTM) | 92.59 | 12.97 | Corcept Therapeutics |
| Enterprise Value | $3.56B | $8.95B | Corcept Therapeutics |
| EV/Revenue Ratio | 79.62 | 12.50 | Corcept Therapeutics |
| Gross Profit Margin (TTM) | N/A | 98.23% | N/A |
| Revenue per Share (TTM) | $1 | $7 | Corcept Therapeutics |
| Earnings per Share (Diluted) | $-3.49 | $1.12 | Corcept Therapeutics |
| Beta (Stock Volatility) | 2.27 | 0.46 | Corcept Therapeutics |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Kymera Therapeutics vs Corcept Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Kymera Therapeutics | -0.60% | -1.62% | 33.03% | 31.36% | 161.47% | 40.74% |
| Corcept Therapeutics | 1.93% | 7.09% | 26.14% | 33.01% | 20.36% | 79.81% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Kymera Therapeutics | 27.83% | 161.59% | 49.95% | 73.03% | 73.03% | 73.03% |
| Corcept Therapeutics | 97.78% | 230.09% | 399.17% | 2,197.95% | 2,308.85% | 1,704.22% |
News Based Sentiment: Kymera Therapeutics vs Corcept Therapeutics
Kymera Therapeutics
News based Sentiment: POSITIVE
Kymera experienced a highly positive month marked by strategic partnerships with Sanofi and Gilead, significant progress across its clinical pipeline, and a wave of analyst upgrades. These developments signal growing confidence in the company's potential and have driven substantial stock performance, making it a noteworthy event for investors.
Corcept Therapeutics
News based Sentiment: MIXED
Corcept experienced a month of conflicting signals, with strong sales of Korlym countered by lowered revenue guidance and a projected earnings decline. The upcoming FDA decisions on relacorilant are critical catalysts, but the recent insider selling and mixed analyst ratings add complexity to the investment picture.
Performance & Financial Health Analysis: Kymera Therapeutics vs Corcept Therapeutics
| Metric | KYMR | CORT |
|---|---|---|
| Market Information | ||
| Market Cap | $4.26B | $9.29B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 879,850 | 733,300 |
| 90 Day Avg. Volume | 836,827 | 831,183 |
| Last Close | $57.55 | $89.85 |
| 52 Week Range | $19.44 - $59.00 | $42.01 - $117.33 |
| % from 52W High | -2.46% | -23.42% |
| All-Time High | $91.92 (Dec 28, 2020) | $117.33 (Mar 31, 2025) |
| % from All-Time High | -37.39% | -23.42% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.55% | 0.19% |
| Quarterly Earnings Growth | -0.55% | -0.01% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.19% |
| Operating Margin (TTM) | -7.37% | 0.14% |
| Return on Equity (TTM) | -0.33% | 0.22% |
| Debt to Equity (MRQ) | 8.82 | 1.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.77 | $6.04 |
| Cash per Share (MRQ) | $9.31 | $3.25 |
| Operating Cash Flow (TTM) | $-251,008,000 | $182.19M |
| Levered Free Cash Flow (TTM) | $-153,841,376 | $166.88M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Kymera Therapeutics vs Corcept Therapeutics
| Metric | KYMR | CORT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -19.43 | 78.71 |
| Forward P/E | -18.62 | 50.37 |
| PEG Ratio | -0.30 | -26.76 |
| Price to Sales (TTM) | 92.59 | 12.97 |
| Price to Book (MRQ) | 4.21 | 14.60 |
| Market Capitalization | ||
| Market Capitalization | $4.26B | $9.29B |
| Enterprise Value | $3.56B | $8.95B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 79.62 | 12.50 |
| Enterprise to EBITDA | -11.67 | 87.24 |
| Risk & Other Metrics | ||
| Beta | 2.27 | 0.46 |
| Book Value per Share (MRQ) | $13.77 | $6.04 |
Financial Statements Comparison: Kymera Therapeutics vs Corcept Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | KYMR | CORT |
|---|---|---|
| Revenue/Sales | $11.48M | $157.21M |
| Cost of Goods Sold | N/A | $2.40M |
| Gross Profit | N/A | $154.81M |
| Research & Development | $78.39M | $60.74M |
| Operating Income (EBIT) | $-84.56M | $3.42M |
| EBITDA | $-74.42M | $3.88M |
| Pre-Tax Income | $-76.61M | $9.62M |
| Income Tax | N/A | $-10.93M |
| Net Income (Profit) | $-76.61M | $20.55M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | KYMR | CORT |
|---|---|---|
| Cash & Equivalents | $89.97M | $89.82M |
| Total Current Assets | $500.95M | $438.50M |
| Total Current Liabilities | $58.99M | $143.07M |
| Long-Term Debt | $73.09M | $5.85M |
| Total Shareholders Equity | $786.23M | $683.29M |
| Retained Earnings | $-820.19M | $564.28M |
| Property, Plant & Equipment | $18.88M | $7.69M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | KYMR | CORT |
|---|---|---|
| Operating Cash Flow | $-67.71M | $34.72M |
| Capital Expenditures | $-467,000 | $-104,000 |
| Free Cash Flow | $-79.62M | $5.02M |
| Debt Repayment | $-277,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | KYMR | CORT |
|---|---|---|
| Shares Short | 7.46M | 10.81M |
| Short Ratio | 11.82 | 16.33 |
| Short % of Float | 0.13% | 0.14% |
| Average Daily Volume (10 Day) | 879,850 | 733,300 |
| Average Daily Volume (90 Day) | 836,827 | 831,183 |
| Shares Outstanding | 64.89M | 105.11M |
| Float Shares | 46.96M | 86.95M |
| % Held by Insiders | 0.03% | 0.12% |
| % Held by Institutions | 1.12% | 0.76% |
Dividend Analysis & Yield Comparison: Kymera Therapeutics vs Corcept Therapeutics
| Metric | KYMR | CORT |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |